HELIOS Park-Klinikum Leipzig GmbH
- Address
- Struempellstrasse 41, Probstheida, 04289 Leipzig, Germany
Cardiovascular Diseases
At HELIOS Park‑Klinikum Leipzig, researchers are investigating how adding a SGLT2 inhibitor to standard antihypertensive therapy can reduce major cardiovascular and renal events in patients with arterial hypertension.
- Evaluation of cardiovascular outcomes with SGLT2 inhibition
- Impact on renal function in hypertensive patients
- Integration of novel agents into hypertension management
These studies aim to improve long‑term health for people living with high blood pressure and to set new standards for preventive cardiology.
Neoplasms
The site conducts trials targeting metastatic colorectal cancer with liver‑dominant disease, evaluating intensified melphalan/HDS chemotherapy followed by combination therapy to extend hepatic progression‑free survival.
- Advanced chemotherapy regimens for liver‑dominant colorectal metastases
- Combination of cytoreductive therapy with anti‑angiogenic agents
- Strategies to delay hepatic progression in refractory disease
The goal is to offer patients more effective treatment options and improve survival outcomes in advanced colorectal cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Delcath Systems Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Park-Klinikum Leipzig GmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Melphalan/HDS Induction Followed by Trifluridine-Tipiracil and Bevacizumab Versus Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | Delcath Systems Inc. | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 1 | Unknown | 2025-12-01 | 2025-12-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.